Chimeric Therapeutics (ASX:CHM) secured a US patent allowance for its CHM CDH17 chimeric antigen receptor technology, a CAR-T therapy targeting gastrointestinal cancers, according to a Tuesday filing with the Australian bourse.
The patent application is for compositions and methods for retrieving tumor-related antibodies and antigens, the filing said.
The patent allowance is expected to provide patent protection until at least 2039.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。